Holen Sie sich die Stockscreener-App
1.05
0.94%
-0.01
Handel nachbörslich:
1.03
-0.02
-1.90%
Schlusskurs vom Vortag:
$1.06
Offen:
$1.06
24-Stunden-Volumen:
87,608
Relative Volume:
0.56
Marktkapitalisierung:
$44.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.00M
KGV:
-0.6918
EPS:
-1.5178
Netto-Cashflow:
$-4.66M
1W Leistung:
+5.85%
1M Leistung:
+0.96%
6M Leistung:
-25.00%
1J Leistung:
-22.22%
1-Tages-Spanne:
$1.02
$1.07
1-Wochen-Bereich:
$0.95
$1.20
52-Wochen-Spanne:
$0.90
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Firmenname
Mira Pharmaceuticals Inc
Sektor
Telefon
813-369-5150
Adresse
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.05 | 44.54M | 0 | -32.00M | -4.66M | -1.5178 |
LLY
Lilly Eli Co
|
1,082.20 | 985.37B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
223.51 | 542.42B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.93 | 384.67B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
115.17 | 293.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
179.71 | 287.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
MIRA News | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN - Black Hills Pioneer
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide - Investing.com UK
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide By Investing.com - Investing.com Nigeria
MIRA Expands Global Ketamir-2 License for Clinical Development - TipRanks
Mira Pharmaceuticals enters into amendment no 1 to exclusive license agreement with Miralogx - marketscreener.com
MIRA Pharmaceuticals (MIRA) expands Ketamir-2 license to worldwide IP rights - Stock Titan
Experimental oral chemo nerve damage drug gets IP boost in 10 countries - Stock Titan
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Weakness Phase - thelegaladvocate.com
MIRA Q3 2025 Earnings: Narrowed Loss Surpasses Expectations Amid No RevenueCFO Commentary Report - thelegaladvocate.com
MIRA Stock Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals (MIRA) Q3 2025 Earnings: Why the Beat MattersRising Community Picks - Newser
What MIRA Pharmaceuticals (MIRA)'s +1.35% Jump Means for Investors 2026-05-18Sentiment Extreme - thelegaladvocate.com
What's going on with MIRA Pharma stock Tuesday? - MSN
Should You Sell MIRA Pharmaceuticals (MIRA) After -1.24% Drop? 2026-05-15Golden Cross - Newser
MIRA Pharmaceuticals (MIRA) Delivers Q3 2025 Beat — EPS $-0.06 vs $-0.08 ExpectedAnalyst Stock Picks - Newser
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 - Investing.com UK
Mira Pharmaceuticals stock gains on Phase 1 trial results By Investing.com - Investing.com South Africa
Mira Pharmaceuticals stock gains on Phase 1 trial results - Investing.com
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 By Investing.com - Investing.com Canada
Chemo nerve damage has no FDA drugs—MIRA advances new Ketamir-2 pill - Stock Titan
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results - TipRanks
MIRA (MIRA) posts positive Phase 1 data and DEA decision on Ketamir-2 - Stock Titan
MIRA Pharmaceuticals Announces Publication of Preclinical Data on SKNY-1 for Obesity and Nicotine Addiction in International Journal of Molecular Sciences 8910 - Minichart
Mira Pharmaceuticals announces peer-reviewed publication of SKNY-1 preclinical data - Investing.com Nigeria
MIRA publishes preclinical study on obesity drug candidate SKNY-1 By Investing.com - Investing.com South Africa
MIRA publishes preclinical study on obesity drug candidate SKNY-1 - Investing.com
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate - ACCESS Newswire
MIRA highlights SKNY-1 preclinical data in new publication - TipRanks
Fish study: MIRA test pill cuts weight 30% and dampens nicotine-seeking - Stock Titan
MIRA Pharmaceuticals publishes preclinical SKNY-1 study showing weight loss, lipid benefits - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) highlights SKNY-1 preclinical obesity and nicotine data - Stock Titan
Is MIRA Pharmaceuticals (MIRA) stock hiding in plain sight? (Wavering) 2026-05-11Crowd Entry Points - Newser
Number of shareholders of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) Top Loser | Q3 2025: Profit SurprisesPost Earnings - UBND thành phố Hải Phòng
Should I buy MIRA Pharmaceuticals (MIRA) stock right now | Q3 2025: EPS Exceeds ExpectationsMargin of Safety - UBND thành phố Hải Phòng
Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):